SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence

T-cell immunity is likely to play a role in protection against SARS-CoV-2 by helping generate neutralizing antibodies. We longitudinally studied CD4 T-cell responses to the M, N, and S structural proteins of SARS-CoV-2 in 26 convalescent individuals. Within the first two months following symptom onset, a majority of individuals (81%) mounted at least one CD4 T-cell response, and 48% of individuals mounted detectable SARS-CoV-2-specific circulating T follicular helper cells (cTfh, defined as CXCR5+PD1+ CD4 T cells). SARS-CoV-2-specific cTfh responses across all three protein specificities correlated with antibody neutralization with the strongest correlation observed for S protein-specific responses. When examined over time, cTfh responses, particularly to the M protein, increased in convalescence, and robust cTfh responses with magnitudes greater than 5% were detected at the second convalescent visit, a median of 38 days post-symptom onset. CD4 T-cell responses declined but persisted at low magnitudes three months and six months after symptom onset. These data deepen our understanding of antigen-specific cTfh responses in SARS-CoV-2 infection, suggesting that in addition to S protein, M and N protein-specific cTfh may also assist in the development of neutralizing antibodies and that cTfh response formation may be delayed in SARS-CoV-2 infection.

[1]  M. Davenport,et al.  Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 , 2021, Nature communications.

[2]  M. Nussenzweig,et al.  Evolution of antibody immunity to SARS-CoV-2 , 2021, Nature.

[3]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[4]  P. Dormitzer,et al.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.

[5]  J. Greenbaum,et al.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.

[6]  V. Shinde,et al.  Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine , 2020, The New England journal of medicine.

[7]  E. Callaway The coronavirus is mutating — does it matter? , 2020, Nature.

[8]  T. Jin,et al.  Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals. , 2020, The Journal of clinical investigation.

[9]  P. Doherty,et al.  Suboptimal SARS-CoV-2−specific CD8+ T cell response associated with the prominent HLA-A*02:01 phenotype , 2020, Proceedings of the National Academy of Sciences.

[10]  L. Carter,et al.  Functional SARS-CoV-2-specific immune memory persists after mild COVID-19 , 2020, medRxiv.

[11]  E. Walsh,et al.  Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults , 2020, Nature.

[12]  O. Kutsch,et al.  Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection , 2020, medRxiv.

[13]  U. Reimer,et al.  SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 , 2020, Nature.

[14]  Nguyen H. Tran,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial , 2020, The Lancet.

[15]  Kelsey K. Finn,et al.  The Loss of Bcl-6 Expressing T Follicular Helper Cells and the Absence of Germinal Centers in COVID-19. , 2020, SSRN.

[16]  Sasikanth Manne,et al.  Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications , 2020, Science.

[17]  Martin Linster,et al.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.

[18]  J. Mascola,et al.  An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.

[19]  Nichollas E. Scott,et al.  Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19 , 2020, Nature Medicine.

[20]  C. Agrati,et al.  Immunological and inflammatory profiles in mild and severe cases of COVID-19 , 2020, Nature Communications.

[21]  A. Sette,et al.  Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome , 2020, Science Immunology.

[22]  C. Rice,et al.  Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses , 2020, bioRxiv.

[23]  W. Greene,et al.  SARS-CoV-2-specific T cells exhibit phenotypic features reflecting robust helper function, lack of terminal differentiation, and high proliferative potential , 2020, bioRxiv.

[24]  G. Wei,et al.  Mutations Strengthened SARS-CoV-2 Infectivity , 2020, Journal of Molecular Biology.

[25]  L. Du,et al.  The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation , 2020, Vaccines.

[26]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[27]  R. Baric,et al.  DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.

[28]  P. Sorger,et al.  SARS-CoV-2 infection protects against rechallenge in rhesus macaques , 2020, Science.

[29]  Jianpeng Xiao,et al.  Prolonged Persistence of SARS-CoV-2 RNA in Body Fluids , 2020, Emerging infectious diseases.

[30]  M. Wener,et al.  Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho , 2020, Journal of Clinical Microbiology.

[31]  Xinquan Wang,et al.  Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals , 2020, Immunity.

[32]  Jianjun Liu,et al.  Coronavirus Disease 2019 Test Results After Clinical Recovery and Hospital Discharge Among Patients in China , 2020, JAMA network open.

[33]  M. Girardis,et al.  Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia , 2020, Nature Communications.

[34]  Yong-tang Zheng,et al.  Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[35]  B. Cowie,et al.  Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 , 2020, Nature Medicine.

[36]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[37]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[38]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[39]  A. Westfall,et al.  Peripheral CD4 T follicular cells induced by a conjugated pneumococcal vaccine correlate with enhanced opsonophagocytic antibody responses in younger individuals. , 2020, Vaccine.

[40]  E. Wherry,et al.  T follicular helper cells in human efferent lymph retain lymphoid characteristics. , 2019, The Journal of clinical investigation.

[41]  Paul A. Harris,et al.  The REDCap consortium: Building an international community of software platform partners , 2019, J. Biomed. Informatics.

[42]  R. Koup,et al.  Altered immune cell follicular dynamics in HIV infection following influenza vaccination , 2018, The Journal of clinical investigation.

[43]  S. Kalayanarooj,et al.  Activation of Peripheral T Follicular Helper Cells During Acute Dengue Virus Infection , 2018, The Journal of infectious diseases.

[44]  D. Kaufmann,et al.  Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells , 2017, PloS one.

[45]  A. Aderem,et al.  Vaccination establishes clonal relatives of germinal center T cells in the blood of humans , 2017, The Journal of experimental medicine.

[46]  Alessandro Sette,et al.  A Cytokine-Independent Approach To Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood , 2016, The Journal of Immunology.

[47]  M. Carrington,et al.  HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4+ T Cell Responses , 2015, Journal of Virology.

[48]  K. Überla,et al.  Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells , 2015, The Journal of Immunology.

[49]  H. Streeck,et al.  Emerging concepts on T follicular helper cell dynamics in HIV infection. , 2014, Trends in immunology.

[50]  Alessandro Sette,et al.  Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. , 2013, Immunity.

[51]  C. Mackay,et al.  Circulating precursor CCR7(lo)PD-1(hi) CXCR5⁺ CD4⁺ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. , 2013, Immunity.

[52]  Virginia Pascual,et al.  Induction of ICOS+CXCR3+CXCR5+ TH Cells Correlates with Antibody Responses to Influenza Vaccination , 2013, Science Translational Medicine.

[53]  K. Legge,et al.  Pulmonary Infection with Influenza A Virus Induces Site-Specific Germinal Center and T Follicular Helper Cell Responses , 2012, PloS one.

[54]  C. Mackay,et al.  CXCR5 Expressing Human Central Memory CD4 T Cells and Their Relevance for Humoral Immune Responses , 2011, The Journal of Immunology.

[55]  M. Altfeld,et al.  Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 , 2011, PLoS pathogens.

[56]  T. Strutt,et al.  Regulation of CD4+ T‐cell contraction during pathogen challenge , 2010, Immunological reviews.

[57]  Christopher D. Paddock,et al.  Cellular Immune Responses to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection in Senescent BALB/c Mice: CD4+ T Cells Are Important in Control of SARS-CoV Infection , 2009, Journal of Virology.

[58]  Zoe Moodie,et al.  Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. , 2007, Journal of immunological methods.

[59]  M. Altfeld,et al.  Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. , 2003, Journal of immunological methods.

[60]  W. Mcclements,et al.  A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified ELISpot assay. , 2001, Journal of immunological methods.